BR112012010054A2 - compostos quinuclidina como ligantes de receptor de acetilcolina alfa-7 nicotínicos - Google Patents

compostos quinuclidina como ligantes de receptor de acetilcolina alfa-7 nicotínicos

Info

Publication number
BR112012010054A2
BR112012010054A2 BR112012010054A BR112012010054A BR112012010054A2 BR 112012010054 A2 BR112012010054 A2 BR 112012010054A2 BR 112012010054 A BR112012010054 A BR 112012010054A BR 112012010054 A BR112012010054 A BR 112012010054A BR 112012010054 A2 BR112012010054 A2 BR 112012010054A2
Authority
BR
Brazil
Prior art keywords
compounds
acetylcholine receptor
receptor ligands
nicotinic alpha
quinuclidine compounds
Prior art date
Application number
BR112012010054A
Other languages
English (en)
Inventor
Christiana I Iwuagwu
Dalton King
F Christopher Zusi
Ivar M Mcdonald
James H Ii Cook
John E Macor
Nenghui Wang
Richard E Olson
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR112012010054A2 publication Critical patent/BR112012010054A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

compostos quinuclidina como ligantes de receptor de acetilcolina alfa-7 nicotínicos. a presente invenção refere-se a compostos de fórmula i incluindo seus sais, bem como a composições e a métodos de uso dos compostos. os compostos são ligantes para o receptor 7 nicotínico e podem ser úteis para o tratamento de vários distúrbios do sistema nervoso centra, especialmente distúrbios afetivos e neurodegenerativos.
BR112012010054A 2009-10-29 2009-10-29 compostos quinuclidina como ligantes de receptor de acetilcolina alfa-7 nicotínicos BR112012010054A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2009/062492 WO2011053292A1 (en) 2009-10-29 2009-10-29 Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands

Publications (1)

Publication Number Publication Date
BR112012010054A2 true BR112012010054A2 (pt) 2016-05-24

Family

ID=41361291

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012010054A BR112012010054A2 (pt) 2009-10-29 2009-10-29 compostos quinuclidina como ligantes de receptor de acetilcolina alfa-7 nicotínicos

Country Status (14)

Country Link
EP (1) EP2493892B1 (pt)
JP (1) JP5619907B2 (pt)
KR (1) KR20120099060A (pt)
CN (1) CN102791718B (pt)
AU (1) AU2009354790A1 (pt)
BR (1) BR112012010054A2 (pt)
CA (1) CA2779177C (pt)
EA (1) EA201270610A1 (pt)
ES (1) ES2544970T3 (pt)
IL (1) IL219366A0 (pt)
MX (1) MX2012004560A (pt)
NZ (1) NZ600240A (pt)
TN (1) TN2012000191A1 (pt)
WO (1) WO2011053292A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2812608C (en) 2010-10-06 2020-07-14 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
AR090037A1 (es) 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
KR102226489B1 (ko) * 2012-07-27 2021-03-11 사토 파머슈티컬 가부시키가이샤 디플루오로메틸렌 화합물
EP3215512A1 (en) * 2014-11-04 2017-09-13 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
JP7032903B2 (ja) * 2016-10-12 2022-03-09 田辺三菱製薬株式会社 スルホンアミド化合物の製造方法
CN116217571A (zh) * 2023-03-28 2023-06-06 上海锐谱医药科技有限公司 一种制备药物砌块1,2,4-三唑并[4,3-a]吡啶-3-胺的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8808433D0 (en) * 1988-04-11 1988-05-11 Merck Sharp & Dohme Therapeutic agents
IL97726A (en) * 1990-04-10 1994-12-29 Israel Inst Biolog Res Pharmaceutical preparations containing compounds with bridged and unbridged heterocyclic groups connected via spiro-atop with oxazoline and thiazoline groups, and sharp compounds
US5534520A (en) * 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
US20080113983A1 (en) * 2004-12-15 2008-05-15 Astrazeneca Ab Nicotinic Acetylcholine Receptor Ligands
ITMI20061279A1 (it) * 2006-06-30 2008-01-01 Consiglio Nazionale Ricerche Agonisti nicotinici selettivi per il sottotipo recettoriale alfa7,procedimento per la loro preparazione e relative composizioni farmaceutiche
US7863291B2 (en) * 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands

Also Published As

Publication number Publication date
CN102791718A (zh) 2012-11-21
WO2011053292A1 (en) 2011-05-05
JP5619907B2 (ja) 2014-11-05
KR20120099060A (ko) 2012-09-06
MX2012004560A (es) 2012-05-08
CA2779177A1 (en) 2011-05-05
IL219366A0 (en) 2012-06-28
CN102791718B (zh) 2015-11-25
NZ600240A (en) 2014-04-30
EA201270610A1 (ru) 2013-02-28
ES2544970T3 (es) 2015-09-07
EP2493892A1 (en) 2012-09-05
TN2012000191A1 (en) 2013-12-12
JP2013509405A (ja) 2013-03-14
AU2009354790A1 (en) 2012-06-14
EP2493892B1 (en) 2015-07-01
CA2779177C (en) 2016-08-30

Similar Documents

Publication Publication Date Title
EA201001696A1 (ru) СОЕДИНЕНИЯ ХИНУКЛИДИНА В КАЧЕСТВЕ ЛИГАНДОВ НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА α7
BR112014026176A2 (pt) dipiridilaminas substituídas e usos das mesmas
BR112014011850A8 (pt) Derivados de aminopirimidina, seus usos, e composição farmacêutica
BR112015015812A2 (pt) derivados de pirimidina fundidos a pirido ou pirrolo como inibidores de autotaxina para tratamento de dor
CL2008002271A1 (es) (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida o su sal farmaceutica; proceso de preparacion; compuestos intermediarios; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para tratar un trastorno del sistema nervioso central tal como alzheimer, demencia senil, parkinson.
BR112012010054A2 (pt) compostos quinuclidina como ligantes de receptor de acetilcolina alfa-7 nicotínicos
BR112015002118A2 (pt) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
BR112014012217A2 (pt) derivados de 2-fenilaminopirimidina como moduladores de cinase lrrk2 para o tratamento de doença de parkinson
BR112015016395A2 (pt) pirazóis 3-substituídos e uso como inibidores de dlk
UA109792C2 (uk) Індоли як противірусні агенти відносно респіраторного синтиціального вірусу
BR112014002675A2 (pt) "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição"
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
BR112014022000A8 (pt) compostos à base de pirazol[1,5-a]pirimidina, seu uso e composições que os compreende
BR112012029405A8 (pt) compostos macrocíclicos como inibidores de trk quinase
BR112014013108A2 (pt) compostos tricíclicos fundidos como inibidores da quinase raf
BR112014010420A2 (pt) inibidores de pak para o tratamento de distúrbios proliferativos celulares
UA113641C2 (xx) Інгібітори бета-секретази
BR112015010412A2 (pt) compostos heteroaromáticos e seu uso como ligantes de dopamina d1
BR112014003079A2 (pt) derivado de 1,2,3,4-tetra-hidroquinolina útil para o tratamento de diabetes
PH12015501293A1 (en) Imidazopyridazine derivatives as gabaa receptor modulators
BR112013026397A2 (pt) Compostos cromenona como inibidores de pi 3-cinase para o tratamento de câncer
BR112012009121A2 (pt) Novas composições para a prevenção e/ou tratamento de distúrbios degenerativos do sistema nervoso central
BR112013019160A2 (pt) novos compostos, composição farmacêutica, uso, processos e métodos
BR112012013325B8 (pt) composição farmacêutica e uso
BR112015020834A2 (pt) novos derivados hidroquinolina-2-ona como inibidores de aldosterona sintetase (cyp1 1 b2 ou cyp1 1 b1)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]